Augclav

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Augclav

Property Description
Active ingredients Amoxicillin, Clavulanic acid
Forms Tablet, Oral suspension, Injectable powder
Pharmacological class beta-Lactam antibiotic, beta-Lactamase inhibitor combination
Common use Combating bacterial infections
Origin Synthetic

What Type of Medicine is Augclav (Co-amoxiclav)?

Augclav is the trade name for a fixed-dose combination antibiotic known generically as Co-amoxiclav, which is used to combat bacterial infections. This medicine is scientifically classified as a beta-lactam antibiotic, belonging specifically to the penicillin-class of antimicrobial agents.

The medicine's classification is based on its core components, Amoxicillin and Clavulanic acid, which are synthetic compounds designed for systemic use against a wide array of susceptible microorganisms. This combination is an effective therapeutic option for infections caused by beta-lactamase-producing bacteria. The efficacy of this pairing is widely clinically recognized for managing common infections where resistance is suspected.


Composition: Amoxicillin, Clavulanic Acid, and Physical Forms

The drug is composed of two primary active ingredients: Amoxicillin and Clavulanic acid. Amoxicillin functions as the primary bactericidal agent, working to destroy the bacteria, while Clavulanic acid acts as a crucial protective element. This combination is categorized as an essential medicine due to its recognized efficacy and importance in addressing healthcare needs.

The role of Clavulanic acid is to inhibit bacterial defense mechanisms, specifically the beta-lactamase enzymes. This protective function ensures that the Amoxicillin component remains potent enough to eliminate the target bacteria. Augclav is manufactured in several dosage forms suitable for administration, including oral tablets (often film-coated tablet), oral suspension for liquid dosing, and an injectable powder for parenteral (intravenous) administration.


General Purpose: Overcoming Resistance in Bacterial Infections

The general purpose of Augclav is to provide a potent antimicrobial action capable of managing illnesses caused by susceptible bacteria. The combination is fundamentally engineered to address the common challenge of bacterial resistance.

The mechanism of resistance overcoming is considered a significant therapeutic advancement. By neutralizing the bacterial enzymes that attempt to deactivate the antibiotic, this fixed-dose combination product effectively provides broad-spectrum activity. The medicine’s design ensures the Amoxicillin component can successfully perform its essential function of killing the bacteria, leading to a successful resolution of the underlying bacterial infection.

Regulatory References

  1. Amoxicillin Clavulanate - StatPearls - NCBI Bookshelf

What side effects are possible with Augclav?

Possible Side Effects and Safety Information

The official regulatory safety profile for Augclav (Amoxicillin/Clavulanic acid) establishes the types and frequencies of possible side effects. Adverse reactions are grouped by the affected System-Organ Class as documented in the prescribing information, including the Gastrointestinal, Skin and Subcutaneous Tissue, and Hepatobiliary systems.

Diarrhoea/loose stools is classified as a very common adverse reaction, meaning it is reported in over 1 in 10 individuals in some populations. Other common effects include mucocutaneous candidosis (thrush), nausea, and vomiting, which are reported in up to 1 in 10 patients.

Serious Adverse Reactions and Safety Constraints

The medicine's regulatory label documents the potential for serious adverse reactions, though these occur at a lower frequency. These include severe, sometimes fatal, hypersensitivity reactions (anaphylaxis) and major cutaneous conditions like Stevens-Johnson Syndrome (SJS). Clinically significant hepatic dysfunction, such as hepatitis and cholestatic jaundice, is also documented, with these effects occasionally appearing several weeks after cessation of treatment.

Official safety notes specify that the medicine is contraindicated in individuals with a history of serious allergic reaction to any penicillin or other beta-lactam antibiotic, or a history of drug-associated liver problems. Population-specific considerations note that hepatic events have been reported predominantly in older adults and that convulsions may occur in patients with impaired renal function.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Augclav (amoxicillin/clavulanate) can lead to a range of symptoms, primarily affecting the gastrointestinal and renal systems. All overdose situations require immediate medical assessment.

Overdose Presentation Key Clinical Manifestations
Gastrointestinal Effects Nausea, vomiting, stomach pain, and diarrhea.
Neurological Effects Drowsiness, hyperactivity, and, in severe cases, seizures.
Renal/Urinary Effects Decreased urination, cloudy urine, or greatly reduced urine output.

Serious or life-threatening events associated with overdose include the risk of seizures and severe disturbances in fluid and electrolyte balance. The extended-release formulation is specifically noted to be unsuitable for patients with severe kidney disease, highlighting a critical population constraint for this type of exposure.


Required Emergency Actions

Immediate medical attention is required for any suspected overdose.

  • Seek Emergency Medical Attention: Contact a poison control center immediately for advice. In the US, the Poison Help line can be reached at 1-800-222-1222.
  • Call Emergency Services (911): If the individual has collapsed, had a seizure, is unresponsive (cannot be awakened), or is experiencing trouble breathing, call emergency services immediately.

All individuals must receive appropriate follow-up care for supportive measures, with specific attention to fluid status and renal function, as defined by medical professionals based on the overdose context.

Therapeutic Uses of Augclav

Augclav (Co-amoxiclav) is a combination antibiotic prescribed to manage various bacterial infections where the presence of antibiotic-resistant bacteria is either known or strongly suspected. The therapeutic intent is focused on bacterial eradication, which assists in addressing the underlying infection and helps to ease the symptom clusters associated with it. This combination is applied across several therapeutic domains.

This medication is commonly used to help with conditions presenting with acute or disruptive symptom patterns, including community-acquired pneumonia, acute bacterial sinusitis, acute otitis media, cellulitis and other skin and soft tissue infections, dental abscesses, and complicated urinary tract infections. It is relevant in clinical settings that involve heightened systemic burden, such as infections following animal bites or surgical procedures.

The combination helps address symptoms related to physical discomfort, such as fever, severe pain, swelling, and breathing difficulties. It provides support that helps ease the overall symptom burden during these acute episodes.

“This medicine is commonly used to help with a wide range of bacterial conditions where supportive broad-spectrum management is appropriate.”


Quick Fact: Relief for Inflammatory Pain

Augclav is relevant for easing intense, localized symptoms, such as the pain and swelling that often accompany severe skin infections or dental abscesses, helping to maintain a sense of stability when symptoms are more noticeable.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Map: Official Regulatory Information

Augclav (Amoxicillin/Clavulanate) eligibility is determined by specific contraindications and required dose adjustments related to a patient's medical history and organ function, as defined in official regulatory labeling.

Category Regulatory Statement
Absolute Contraindications Patients with a history of serious hypersensitivity (e.g., anaphylaxis) to any beta-lactam antibiotic (penicillins, cephalosporins). Patients with a prior history of Augclav-associated cholestatic jaundice or hepatic dysfunction.
Avoid or Use with Caution Patients with Infectious Mononucleosis (due to rash risk) should avoid use. Patients with severe renal impairment ( CrCl < 30 mL/min) or hepatic impairment require cautious use, with mandatory dose adjustment for the former.
Age-Related Status Neonates and infants (< 3 months) are restricted to specific formulations; use in older adults is generally permitted provided renal function is adequate.
Pregnancy/Lactation Use during pregnancy is permitted only when clearly needed, though generally considered safe; caution is advised during breastfeeding due to excretion into milk and potential for infant sensitization or gastrointestinal effects.

Regulatory documents structure the eligibility profile by defining absolute exclusions based on immune and liver history, while imposing conditional use based on the patient's capacity to metabolize and excrete the medicine.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Augclav's interaction profile is defined by pharmacokinetic effects on renal clearance and pharmacodynamic risk enhancement, as documented in regulatory sources (FDA, EMA/SmPC).


Interaction scope

Category Official Regulatory Information
Medicinal product categories with documented interactions Oral Anticoagulants; Renal clearance inhibitors (e.g., Probenecid); Uricosuric agents (e.g., Allopurinol); Immunosuppressants (e.g., Methotrexate, Mycophenolate Mofetil).
Mechanistic basis of interactions (only if stated in label) Inhibition of renal tubular secretion (Amoxicillin clearance); Pharmacodynamic effect on coagulation; Impairment of enterohepatic recirculation (affecting MMF).
Timing-based interaction rules (if applicable) Must be administered at the start of a meal to optimise absorption.
Population-specific interaction notes (if applicable) The interaction with oral anticoagulants, leading to an increased risk of bleeding, may be particularly notable in older patients or those with liver or kidney diseases.

Interaction classifications (high-level)

Category Classification Details (Strictly Regulatory)
Interaction severity classification (as defined in official documents) Not Recommended Combination (Probenecid); Use with Caution/Monitoring Required (Oral Anticoagulants); Contra-indicated (Anti-peristaltic agents in specific complication).

Resulting interaction structure

Official interaction statements:

  • Probenecid is not recommended due to inhibition of renal tubular secretion, resulting in increased and prolonged blood levels of amoxicillin.
  • Oral Anticoagulants require monitoring of Prothrombin Time/INR because co-administration may increase the documented risk of bleeding.
  • Co-administration with Allopurinol increases the likelihood of an allergic skin reaction/rash.
  • Methotrexate excretion may be reduced, potentially leading to an increase in toxicity (due to elevated exposure).
  • Use with Oral Contraceptives may reduce the efficacy of the contraceptive agent.
  • The clavulanic acid component can lead to a documented false positive Coombs test result.
  • Anti-peristaltic medicinal products are contra-indicated if the patient develops antibiotic-associated colitis.

Connection to the overall interaction profile (2–4 sentences):

Regulatory documents define the interaction profile primarily through pharmacokinetic effects that necessitate drug exposure monitoring and pharmacodynamic effects that compound adverse event risk. This structure results in specific restrictions and mandatory use-with-caution statements for substances that significantly alter clearance or compound risks, ensuring consistency with official label constraints.

Mechanism of Action

The action of Augclav (Co-amoxiclav) is a synergistic process achieved by two distinct molecular mechanisms that work together to overcome bacterial defense. The overall consequence is the direct, bactericidal effect on susceptible bacteria.

Blocking Key Enzymes in Bacterial Cell Wall Synthesis

The Amoxicillin component acts as an irreversible inhibitor of essential Penicillin-Binding Proteins (PBPs) found within the bacterial cell wall. These enzymes are vital for the peptidoglycan cross-linking process—the final stage of cell wall assembly. By preventing this structural step, the mechanism causes the bacterial cell to lose its integrity and mechanical strength. This molecular interference leads to the cell's inability to withstand its internal pressure, resulting in cell lysis (rupture) and death, a core physiological consequence leading to a decrease in the viable population of microorganisms.

️ Neutralizing Bacterial Defense Enzymes (beta-Lactamases)

The Clavulanic acid component acts by targeting and irreversibly deactivating bacterial beta-Lactamase enzymes. Clavulanic acid functions as a suicide substrate, sacrificing itself to permanently bind to these defense enzymes, which would otherwise hydrolyze and inactivate Amoxicillin. This neutralization mechanism ensures Amoxicillin remains available to execute its cell wall inhibition mechanism, thereby restoring the inhibitory action of Amoxicillin against bacteria that have developed resistance through beta-lactamase production.

Dosage and Administration Information

Official Administration Guidelines for Augclav (Co-amoxiclav)

Augclav's administration and dosage instructions are defined to ensure proper use of the Amoxicillin and Clavulanic acid combination. All usage parameters are based on established clinical and therapeutic protocols.

Feature Official Instruction
Route of Administration Oral (tablets, suspension) or Intravenous (IV) injection/infusion for severe or initial infections.
Timing in Relation to Meals Take at the start of a meal to minimize potential gastrointestinal intolerance and enhance the absorption of the clavulanate component.
Frequency Pattern Typically dosed Every 12 hours (twice daily) or Every 8 hours (three times daily), depending on the specific strength and formulation used.
Standard Adult Oral Dosing Ranges from 500 mg every 12 hours to 875 mg every 12 hours, based on the amoxicillin component and the specific regimen.
Course Duration Treatment should generally not be extended beyond 14 days without a clinical review.

Population-Specific and Procedural Rules

  • Pediatric Dosing The dose for children weighing less than 40 kg is calculated based on body weight (mg/kg/day).
  • Renal Impairment Dose adjustments are required for patients with significant kidney function impairment (Creatinine Clearance leq 30 mL/min). The 875 mg tablet strength is generally not recommended in this population.
  • Tablet Handling Extended-release tablets must be swallowed whole and should not be crushed, broken, or chewed. Different tablet ratios (e.g., 4:1 vs. 7:1 amoxicillin to clavulanic acid) are not substitutable for each other due to differences in clavulanic acid content.
  • Missed Dose A missed dose should be taken as soon as possible, but do not take a double dose to make up for the missed one.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Augclav (Co-amoxiclav)


Evidence for Use in Acute Bacterial Sinusitis and Otitis Media

Acute Bacterial Sinusitis: Research has primarily focused on short-term randomized controlled trials (RCTs) that compare Augclav to various regimens or different dosing levels. These studies monitored outcomes related to symptom evolution and tracked patient-reported experiences in adult outpatients. Findings describe patterns observed in the studies related to outcomes measured included symptom reporting related to facial pain and congestion. Consequently, it is not yet clear whether studies fully address outcomes in patients who might experience spontaneous symptom resolution.

Acute Otitis Media (AOM): For this condition, often presenting as acute or disruptive episodes in young people, the evidence relies heavily on RCTs conducted in pediatric populations. Studies monitored clinical success and bacteriological eradication (the removal of germs from the middle ear fluid) over defined time intervals. Findings describe patterns observed in the studies related to specific clinical responses in the observed populations. Comparative evidence is lacking for specific situations, such as trials examining alternative monotherapy regimens in all current scenarios, and follow-up durations were limited to the immediate post-treatment period.


Evidence for Use in Community-Acquired Pneumonia (CAP)

Research examined the use of Augclav in adults who had pneumonia and required either outpatient management or hospitalization in non-intensive settings. The studies explored clinical outcomes relevant to disease progression, such as study outcomes related to major clinical events, such as survival status and hospital readmission rates. These findings describe patterns observed in the studies related to recovery over the short term. However, comparative evidence is lacking in large, head-to-head trials against all alternative antibiotic classes, which means a comprehensive view of the evidence landscape is limited. Long-term effects are not fully established, as most research monitored responses only for a short time after the treatment course ended.


Research Gaps and Areas of Uncertainty

Despite extensive study, research highlights what is known—and what is still uncertain. Comparative evidence is lacking in comprehensive, head-to-head trials against every competing treatment option. The results apply only to the populations studied, and data for certain groups remain insufficient. The evidence quality varies across studies, especially between large, regulated trials and smaller, regional studies. Additionally, as microbial resistance patterns evolve over time, research is ongoing to ensure current findings remain relevant.

Key Studies & References

  1. Clinical Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by IDSA
  2. Treatment of Acute Sinusitis With High-Dose vs. Standard-Dose Amoxicillin/Clavulanate (NCT03431337)

Frequently Asked Questions (FAQ)

Common questions about Augclav (FAQ)

Q: Is Augclav an antibiotic, and what kind of infections is it usually prescribed for?

Augclav is officially a penicillin-class antibiotic combination. Regulatory documents indicate it is used to treat specific bacterial infections, including those affecting the lower respiratory tract, acute bacterial otitis media (ear infection), sinusitis, skin and skin structures, and the urinary tract. The combination is typically used for infections caused by bacteria known or suspected to produce beta-lactamase enzymes.


Q: Does Augclav have a generic version available?

Yes, Augclav is a brand name for the active components amoxicillin and clavulanate potassium (Co-amoxiclav). Official drug databases confirm that generic forms of this combination medicine are widely manufactured and available.


Q: How long does Augclav stay in your system after you finish taking it?

The time it takes for a medicine to be eliminated is described by its half-life. Regulatory pharmacokinetic information indicates that the half-life of both amoxicillin and clavulanic acid is approximately one hour. This half-life describes the rate at which the components are eliminated from the body.


Q: Is it normal to feel tired or dizzy while on Augclav?

Tiredness or fatigue is not typically listed as a very common side effect in regulatory documents. However, official safety monitoring reports have mentioned that dizziness or lightheadedness may occur in some individuals using this medicine.


Q: Does Augclav interact with common pain relievers like ibuprofen or acetaminophen?

Official labeling highlights formal interactions with medicines that affect kidney clearance, such as Probenecid, and those that affect blood clotting, such as oral anticoagulants. Routine pain relievers like ibuprofen and acetaminophen (paracetamol) are generally not listed as a formal contraindication or formal interaction in the main regulatory documents.


Q: Are there interactions between Augclav and alcohol?

While regulatory documents do not list a formal contraindication with alcohol, it is important to note that consuming alcohol may potentially worsen common gastrointestinal side effects such as nausea and diarrhea.


Q: Are there certain foods or drinks that should be avoided while taking Augclav?

Official administration guidelines state the medicine should be taken at the start of a meal to enhance the absorption of the clavulanate component and minimize stomach upset. Specific regulatory warnings also advise patients with rare glucose-galactose malabsorption should not take specific formulations, as they may contain maltodextrin.


Q: Why does Augclav sometimes cause diarrhea, and what can be done to manage this?

Diarrhea is a very common side effect. The antibiotic component can disrupt the normal balance of microorganisms in the gut. Official safety warnings note that severe, persistent diarrhea can be a sign of a serious condition known as Clostridioides difficile-associated diarrhea (CDAD), which may necessitate medical review.


Q: Are there any studies comparing the combination ingredients in Augclav to single antibiotics?

The regulatory text highlights that the drug is indicated for use against beta-lactamase producing organisms where amoxicillin alone is not effective. Official guidelines sometimes reference the possibility of using amoxicillin alone if susceptibility testing confirms it is appropriate for the infection.


Q: Are there any long-term effects associated with using Augclav?

This medicine is generally used for a short course of up to 14 days. However, regulatory information notes that clinically significant liver problems, such as cholestatic jaundice, have been reported, sometimes occurring several weeks after the treatment course has ended.


Q: What types of bacteria is Augclav designed to target?

The addition of clavulanic acid to amoxicillin helps to extend the drug's activity to cover susceptible beta-lactamase producing bacteria. Official documents classify this spectrum as including certain Gram-positive and Gram-negative organisms.


Q: Is Augclav considered safe for use in the elderly population?

Official guidelines permit the use of Augclav in the elderly, provided their kidney function is adequate. However, safety information specifically notes that liver problems have been reported predominantly in older adults, an element detailed in the drug's safety profile.


Q: Is the research on Augclav still ongoing for new uses?

As bacteria continually evolve and develop resistance, regulatory overviews confirm that research and monitoring are ongoing to ensure current findings and effectiveness against existing indications remain relevant and effective.


Q: Does Augclav affect blood sugar levels?

Official product information notes that the amoxicillin component may cause a false-positive result for glucose in urine when using certain testing methods (such as Benedict's or Fehling's solution). There is no official warning that the drug directly raises blood sugar in patients without specific conditions.


Q: Is Augclav used for dental infections?

The official product label does not explicitly list dental infections as a primary indication. However, professional monographs often include the medicine for the treatment of skin and structure infections or bacterial infections that may occur in the oral cavity.


Q: What should be done if I experience severe stomach pain while taking Augclav?

Official warnings describe severe, persistent abdominal pain or diarrhea as a possible sign of a serious condition like Clostridioides difficile-associated diarrhea (CDAD). Regulatory text specifies that the drug should be discontinued and appropriate therapy instituted if this condition is suspected.


Q: What is the difference between Augclav and Augmentin?

Augmentin is a well-known brand name for the combination drug amoxicillin and clavulanate potassium (Co-amoxiclav) manufactured by a specific company. Augclav is also a brand name for the same active ingredients. If they contain the same dose ratio, they are considered pharmaceutically equivalent.


Q: Is Augclav known to cause headaches?

Headache is not listed among the most common side effects of Augclav. However, official regulatory documents list headache as an uncommon side effect reported with the use of this medicine.


Q: If I have lactose intolerance, can I still take Augclav?

Official product information lists all inactive ingredients, known as excipients. Specific formulations of the medicine, such as certain tablet forms, may contain lactose or maltodextrin, which is important information for patients with rare hereditary issues related to sugar absorption.


Q: Is there any information about Augclav's effect on gut bacteria?

While the term 'gut bacteria' is not used, regulatory documents indirectly address this by classifying diarrhea and thrush as common side effects. They also require screening for Clostridioides difficile-associated diarrhea (CDAD), all of which are related to the disruption of the body’s normal microbial flora.


Q: Is Augclav ever used to prevent infections?

Regulatory guidelines and professional monographs indicate that Amoxicillin/Clavulanate is approved for prophylaxis (prevention) in certain situations. This includes the prevention of infections associated with specific surgical procedures and may be used as prophylaxis following animal bites.


Q: Why do official documents emphasize completing the full course of Augclav?

Regulatory documentation provides the rationale for the prescribed duration of treatment. Warnings state that stopping the medicine too soon or skipping doses may result in the infection not being fully treated and risks the bacteria becoming harder to treat (resistant) to the medicine.

How should Augclav be stored and disposed of?

How to Store and Dispose of Augclav (Amoxicillin and Clavulanate Potassium)

Official storage conditions for Augclav formulations are specific to maintain stability and effectiveness.


Storage Requirements

Formulation Required Condition
Tablets / Dry Powder Store at controlled room temperature (20 C to 25 C).
Reconstituted Suspension Must be refrigerated (2 C to 8 C). Do not freeze.

The dry forms must be kept in the original container and kept tightly closed to protect from moisture. The liquid suspension has a maximum shelf-life of 10 days when refrigerated and must be discarded thereafter.


Disposal and Protection

The medicine must be kept out of the sight and reach of children. Unused or expired Augclav must be disposed of properly according to the official guidelines established by national regulatory authorities.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Augclav found in:

A-Z Index: